Miniature, low-dose, intrauterine drug-delivery systems

Annals of the New York Academy of Sciences

Volumn 997, Issue , 2003, Pages 174-184

  Wildemeersch, D ^a   Dhont, M ^b   Weyers, S ^b   Temmerman, M ^b  

^a Technology Park   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Contraception; Hormone replacement therapy; Intrauterine device (IUD)

Indexed keywords

6 N [2 (3,5 DIMETHOXYPHENYL) 2 (2 METHYLPHENYL)ETHYL]ADENOSINE; CONTRACEPTIVE AGENT; ESTRADIOL; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ENANTATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; STEROID HORMONE;

AMENORRHEA; BLEEDING; BRAIN VASOSPASM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY SPASM; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG RELEASE; DRUG TOLERABILITY; DYSMENORRHEA; ENDOCRINE DISEASE; HEART PROTECTION; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LIPID METABOLISM; LOW DRUG DOSE; MENORRHAGIA; MIGRAINE; POSTMENOPAUSE; PREGNANCY RATE; SIDE EFFECT; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; UTERINE BLEEDING PATTERN; VASOCONSTRICTION; WEIGHT GAIN; ADULT; COMPARATIVE STUDY; CONTRACEPTION; EQUIPMENT; EQUIPMENT DESIGN; FEMALE; METHODOLOGY; MIDDLE AGED; PREGNANCY; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STANDARD;

ADULT; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; EQUIPMENT SAFETY; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; MIDDLE AGED; PREGNANCY; PREGNANCY RATE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 0642364497     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1290.020     Document Type: Conference Paper

References (31)

1. BAIRD, D.T. & A.F. GLASIER. 1999. Science, medicine and the future. Contraception. BMJ 319: 969-972.
2. VANDEBROUCKE, J.P., J. ROSING, K.W.N. BLOEMENKAMP, et al. 2001. Oral contraceptives and the risk of venous thrombosis. N. Engl. J. Med. 344: 1527-1535.
3. MIDDELDORP, S., J. ROSING, B.N. BOUMA & H.R. BÜLLER. 2001. Effecten van orale anticonceptiva van de tweede en derde generatie op de hemostase. Ned. Tijdschr. Geneeskd. 145: 252-256.
4. COLLABORATIVE GROUP ON HORMONAL FACTORS IN BREAST CANCER. 1996. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713-1727.
5. GRAHAM, C.A., R. RAMOS, J. BANCROFT, et al. 1995. The effects of steroidal contraceptives in the well-being and sexuality of women: a double-blind, placebo-controlle, two-centre study of combined and progestin-only methods. Contraception 52:163-169.
6. TRUSSELL, J. & D. KOWAL. 1998. The essentials of contraception. In: Contraceptive Technology. R.A. Hatcher et al. Eds.: 211-248. Ardent Media. New York.
7. THE ALAN GUTTMACHER INSTITUTE. 1999. Sharing Responsibility: Women, Society and Abortion Worldwide. New York.
8. WRITING GROUP FOR THE WOMEN'S HEALTH INITIATIVE INVESTIGATORS. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288: 321-33.
9. TIME MAGAZINE. 2002. The truth about hormones. July 22, 39-44.
10. NACHTIGALL, L. & J.R. HEILMAN. 1986. Estrogen: the facts can change your life. The Body Press. Los Angeles.
11. KUBBA, A. 2000. Non-oral, long-acting hormonal methods of contraception. In Contraceptive Choices and Realities. R.H.W van Lunsen, V. Unzeitig, and G. Creatsas, Eds.: 131-139. Parthenon. London.
12. THIERY, M. 1997. Pioneers of the intruterine device. Eur. J. Contracept. Reprod. Health Care 2:15-23.
13. SODERSTROM, R.M. 1992. The Progestasert® Intrauterine Progesterone Contraceptive System. A new look at IUDs - Advancing contraceptive choices. Proc. Fourth Conf. on IUDs. C.WB. Bardin and D.R. Mishell, Jr., Eds.: 319-327. Butterworths-Heinemann, Boston.
14. WORLD HEALTH ORGANIZATIO. 2000. Department of Reproductive Health and Research. Annu. Rep., Geneva, Switzerland, p. 159.
15. ANDERSSON, K., L.A. MATTSSON, G. RYBO & E. STADBERG. 1992. Intrauterine release of levonorgestrel - A new way of adding progestogen in hormone replacement therapy. Obstet. Gynecol. 79: 963-967.
16. WOLLTER-SVENSSON, L.O., E. STADBERG, K. ANDERSSON, et al. 1995. Intrauterine administration of levonorgestrel in two low doses in HRT. A randomized clinical trial during one year, effects on lipid and lipoprotein metabolism. Maturitas 22: 199-205.
17. BIRKHAÜSER, M.H. 1998. New routes of HRT administration. Int. J. Fertil. 43: 206-207.
18. COX, M. & S. BLACKSELL. 2000. Clinical performance of the levonorgestrel intra-uterine system in routine use by the UK Family Planning and Reproductive Health Research Network, 12-month report. Br. J. Fam. Plann. 26: 143-147.
19. DOLAN, L.M., M. MULHOLLAND & M. PRICE. 2001. The levonorgestrel intra-uterine system: therapeutic application in family planning. J. Fam. Plann. Reprod. Health Care 27: 19-21.
20. COLEMAN, M., L. MCCOWAN & C. FARQUHAR. 1997. The levonorgestrel- releasing intrauterine device: a wider role than contraception. Aust. NZ J. Obstet. Gynaecol. 37: 195-201.
21. WILDEMEERSCH, D., E. SCHACHT, P. WILDEMEERSCH, et al. 2001. Development of a miniature, frameless intrauterine levonorgestrel-releasing system for contraception and treatment: a review of initial clinical experience. Reprod. BioMed. 4: 69-80 (www.rbmonline.com).
22. WU, S., J. HU & D. WILDEMEERSCH. 2000. Performance of the frameless GyneFix and the TCu380A IUDs in a three-year multicenter randomized comparative trial in parous women. Contraception 61: 91-89.
23. WILDEMEERSCH, D. & E. SCHACHT. 2001. Treatment of menorrhagia with a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system, a pilot study. Eur. J. Contracept. Reprod. Health Care 6: 93-101.
24. JANSSENS, D., D. WILDEMEERSCH & M. DHONT. 2002. Klinische resultaten met FibroPlant-LNG, een nieuw LNG IUS voor behandeling en anticonceptie. Gunaïkeia 7: 154-158.
25. ANDREWS, G.D., K. FRENCH & C.L. WILKINSON. 2000. Appropriately trained nurses are competent at inserting intrauterine devices: an audit of clinical practice. Contraceptive Choices and Realities. Proc. 5th Congr. of the European Society of Contraception. R.H.W. van Lunsen, V. Unzeitig, and G. Creatsas, Eds.: 160-163. Parthenon. London.
26. POLANECZKY, M., G. SLAP, C. FORKE, et al. 1994. The use of levonorgestrel implants (Norplant) for contraception in adolescent mothers. N. Engl. J. Med. 331: 1201-1230.
27. TEMPLEMAN, C.L., V. COOK, L.J. GOLDSMITH, et al. 2000. Postpartum contraceptive use among adolescent mothers. Obstet. Gynecol. 95: 770-776.
28. RAUDASKOSKI, T., J. TAPANAINEN, E. TOMÁS, et al. 2002. Intrauterine 10 μg and 20 μg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. Br. J. Obstet. Gynaecol. 109: 136-144.
29. SARREL, P.M. 1999. The differential effects of oestrogens and progestins on vascular tone. Hum. Reprod. Update 5: 205-209.
30. SARREL, P.M. 1995. How progestins compromise the cardioprotective effects of estrogens (Editorial). Menopause 2: 187-190.
31. HILL, D.A., N.S. WEISS & A.Z. LA CROIX. 2000. Adherence to postmenopausal hormone therapy during the year after the initial prescription: a population-based study. Am. J. Obstet. Gynecol. 182: 270-276.